Quantum Biopharma (QNTM) Competitors $16.65 -0.75 (-4.31%) Closing price 04:00 PM EasternExtended Trading$17.36 +0.71 (+4.26%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock QNTM vs. RAPT, TIL, TRDA, SLS, HRTX, IMRX, GNFT, TLSA, EPRX, and CCCCShould you be buying Quantum Biopharma stock or one of its competitors? The main competitors of Quantum Biopharma include Rapt Therapeutics (RAPT), Instil Bio (TIL), Entrada Therapeutics (TRDA), SELLAS Life Sciences Group (SLS), Heron Therapeutics (HRTX), Immuneering (IMRX), GENFIT (GNFT), Tiziana Life Sciences (TLSA), Eupraxia Pharmaceuticals (EPRX), and C4 Therapeutics (CCCC). These companies are all part of the "pharmaceutical products" industry. Quantum Biopharma vs. Its Competitors Rapt Therapeutics Instil Bio Entrada Therapeutics SELLAS Life Sciences Group Heron Therapeutics Immuneering GENFIT Tiziana Life Sciences Eupraxia Pharmaceuticals C4 Therapeutics Rapt Therapeutics (NASDAQ:RAPT) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability. Do analysts recommend RAPT or QNTM? Rapt Therapeutics presently has a consensus target price of $21.57, suggesting a potential upside of 22.36%. Given Rapt Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Rapt Therapeutics is more favorable than Quantum Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapt Therapeutics 0 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50Quantum Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals have more ownership in RAPT or QNTM? 99.1% of Rapt Therapeutics shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 6.6% of Rapt Therapeutics shares are held by insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media refer more to RAPT or QNTM? In the previous week, Rapt Therapeutics had 2 more articles in the media than Quantum Biopharma. MarketBeat recorded 6 mentions for Rapt Therapeutics and 4 mentions for Quantum Biopharma. Rapt Therapeutics' average media sentiment score of 1.14 beat Quantum Biopharma's score of 0.48 indicating that Rapt Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapt Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quantum Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is RAPT or QNTM more profitable? Rapt Therapeutics' return on equity of -67.92% beat Quantum Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Rapt TherapeuticsN/A -67.92% -59.59% Quantum Biopharma N/A -270.22%-131.87% Which has preferable valuation & earnings, RAPT or QNTM? Quantum Biopharma has lower revenue, but higher earnings than Rapt Therapeutics. Rapt Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapt Therapeutics$1.53M190.59-$129.87M-$14.17-1.24Quantum BiopharmaN/AN/A-$14.20M-$14.02-1.19 Which has more volatility & risk, RAPT or QNTM? Rapt Therapeutics has a beta of -0.1, suggesting that its share price is 110% less volatile than the S&P 500. Comparatively, Quantum Biopharma has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. SummaryRapt Therapeutics beats Quantum Biopharma on 10 of the 14 factors compared between the two stocks. Get Quantum Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for QNTM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QNTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNTM vs. The Competition Export to ExcelMetricQuantum BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.40M$3.08B$5.69B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E RatioN/A21.3075.8626.51Price / SalesN/A379.77489.92165.26Price / CashN/A44.4425.8129.89Price / Book3.679.6112.846.32Net Income-$14.20M-$53.28M$3.28B$270.51M7 Day Performance31.21%0.31%0.22%2.15%1 Month Performance-25.84%4.58%4.61%6.35%1 Year Performance319.40%9.24%68.33%25.48% Quantum Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNTMQuantum Biopharma0.491 of 5 stars$16.65-4.3%N/A+345.0%$66.40MN/A0.00N/AGap UpRAPTRapt Therapeutics4.244 of 5 stars$13.28+2.7%$21.57+62.4%+11.7%$213.83M$1.53M-0.9480News CoveragePositive NewsAnalyst UpgradeTILInstil Bio2.8303 of 5 stars$25.77-18.2%$119.00+361.8%-69.5%$212.65MN/A-1.99410High Trading VolumeTRDAEntrada Therapeutics2.5288 of 5 stars$5.28-0.2%$25.67+386.1%-66.3%$201.22M$210.78M-2.97110SLSSELLAS Life Sciences Group1.3438 of 5 stars$1.90-0.5%$7.00+268.4%+27.3%$201.12M$1M-5.9410HRTXHeron Therapeutics4.1311 of 5 stars$1.30-0.8%$4.50+246.2%-33.7%$200.81M$144.29M-65.00300Positive NewsIMRXImmuneering3.4578 of 5 stars$5.95+8.0%$13.00+118.5%+289.1%$200.12M$320K-3.1560Analyst ForecastGap UpGNFTGENFIT1.9069 of 5 stars$3.96+0.5%$9.00+127.3%+3.9%$197.01M$76.77M0.00120Upcoming EarningsTLSATiziana Life Sciences0.5695 of 5 stars$1.62-2.4%N/A+83.8%$193.97MN/A0.008News CoverageShort Interest ↑EPRXEupraxia Pharmaceuticals2.4853 of 5 stars$5.27-2.2%$11.00+108.7%+105.4%$193.82MN/A-6.2029CCCCC4 Therapeutics2.9672 of 5 stars$2.71-0.4%$8.00+195.2%-44.6%$193.59M$35.58M-1.72150News CoverageAnalyst Upgrade Related Companies and Tools Related Companies Rapt Therapeutics Alternatives Instil Bio Alternatives Entrada Therapeutics Alternatives SELLAS Life Sciences Group Alternatives Heron Therapeutics Alternatives Immuneering Alternatives GENFIT Alternatives Tiziana Life Sciences Alternatives Eupraxia Pharmaceuticals Alternatives C4 Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QNTM) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredFree: The Crypto Summit That Could Change Your LifeWall Street’s Crypto Playbook—Revealed at This Free Event If you want to understand what's really happening...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quantum Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quantum Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QNTM Stock Alerts